SCHEMBL4329664

SCHEMBL4329664

Fc1cncc(-c2cc(-c3cccc(F)c3)on2)c1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 4/20 0.54
CYP2C9 P11712 4/20 0.54
CYP2C19 P33261 4/20 0.54
CYP3A4 P08684 3/20 0.54
CYP2D6 P10635 3/20 0.54
RPS6KB1 P23443 1/20 0.53
NPC1 O15118 5/20 0.49
RAB9A P51151 5/20 0.49
HSD17B1 P14061 1/20 0.47
HSD17B2 P37059 1/20 0.47
MAOB P27338 1/20 0.44
TP53 P04637 1/20 0.44
CASP3 P42574 1/20 0.42
SENP8 Q96LD8 1/20 0.42
SENP7 Q9BQF6 1/20 0.42
SENP6 Q9GZR1 1/20 0.42
GRM5 P41594 1/20 0.42
SMN1; SMN2 Q16637 2/20 0.41
MEN1 O00255 2/20 0.41
KMT2A Q03164 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4321601 0.89 NPC1 (0.64) CYP1A2CYP2C9CYP2C19CYP3A4CYP2D6
SCHEMBL4322768 0.89 MAP4K4 (0.46) CYP1A2CYP2C9CYP2C19CYP3A4CYP2D6
SCHEMBL4329713 0.89 RAB9A (0.48) CYP1A2CYP2C9CYP2C19CYP3A4CYP2D6
SCHEMBL4328598 0.88 CYP1A2 (0.54) CYP1A2CYP2C9CYP2C19CYP3A4CYP2D6
SCHEMBL4325908 0.87 CYP2C9 (0.65) CYP1A2CYP2C9CYP2C19CYP3A4CYP2D6
SCHEMBL4333333 0.87 CYP2C19 (0.53) CYP1A2CYP2C9CYP2C19CYP3A4CYP2D6
SCHEMBL4397222 0.86 CYP3A4 (0.53) CYP1A2CYP2C9CYP2C19CYP3A4CYP2D6
SCHEMBL4456071 0.85 CYP3A4 (0.50) CYP1A2CYP2C9CYP2C19CYP3A4CYP2D6
SCHEMBL4331562 0.85 CYP3A4 (0.53) CYP1A2CYP2C9CYP2C19CYP3A4CYP2D6
SCHEMBL4328263 0.84 PTGS2 (0.55) CYP1A2CYP2C9CYP2C19CYP3A4CYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8383658-B2 Isoxazole based neuronal nicotinic receptor ligands and methods of use ABBOTT LABORATORIES (US) 2013-02-26 US claimed
US-20090306096-A1 Novel Isoxazoles and Methods of Use Thereof ABBOTT LABORATORIES (US) 2009-12-10 US claimed
US-8383658-B2 Isoxazole based neuronal nicotinic receptor ligands and methods of use ABBOTT LABORATORIES (US) 2013-02-26 US disclosed
WO-2009149135-A1 BIS (HETERO ) ARYL SUBSTITUTED ISOXAZOLES FOR USE AS NEURONAL NICOTINIC RECEPTOR MODULATORS ABBOTT LABORATORIES (US) 2009-12-10 WO disclosed
US-20090306096-A1 Novel Isoxazoles and Methods of Use Thereof ABBOTT LABORATORIES (US) 2009-12-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090306096-A1 Novel Isoxazoles and Methods of Use Thereof XDH, PRDX5, CYP4X1 CYP1A2 41/4885CYP2C9 136/4885CYP2C19 105/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.